Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Measurements of self-efficacy in musculoskeletal rehabilitation: A systematic review.

Picha KJ, Jochimsen KN, Heebner NR, Abt JP, Usher EL, Capilouto G, Uhl TL.

Musculoskeletal Care. 2018 Sep 20. doi: 10.1002/msc.1362. [Epub ahead of print]

PMID:
30238607
2.

Liberalization and integration of drug distribution in the EU 28 and Norway.

Písek J, Pícha K.

Ceska Slov Farm. 2018 Summer;67(1):14-24.

PMID:
30157663
3.

Patterns and Associations of Shoulder Motion, Strength, and Function in MARSOC Personnel Without History of Shoulder Injury.

Poploski KM, Picha KJ, Winters JD, Royer SD, Heebner NR, Lambert B, Abt JP, Lephart SM.

Mil Med. 2018 Jul 3. doi: 10.1093/milmed/usy088. [Epub ahead of print]

PMID:
29982689
4.

Reliability of 5 Novel Reaction Time and Cognitive Load Protocols.

Picha K, Quintana C, Glueck A, Hoch M, Heebner NR, Abt JP.

J Sport Rehabil. 2018 Sep 1;27(5):1-4. doi: 10.1123/jsr.2018-0042. Epub 2018 Sep 4.

PMID:
29809102
5.

Pitch Volume and Glenohumeral and Hip Motion and Strength in Youth Baseball Pitchers.

Harding JL, Picha KJ, Bliven KCH.

J Athl Train. 2018 Jan;53(1):60-65. doi: 10.4085/1062-6050-323-16. Epub 2017 Dec 28.

PMID:
29283678
6.

Calculation of Resistive Loads for Elastic Resistive Exercises.

Picha K, Uhl T.

J Sport Rehabil. 2018 Mar 1;27(2). doi: 10.1123/jsr.2017-0072. Epub 2018 Mar 14.

PMID:
28952863
7.

Elastic Resistance Effectiveness on Increasing Strength of Shoulders and Hips.

Picha KJ, Almaddah MR, Barker J, Ciochetty T, Black WS, Uhl TL.

J Strength Cond Res. 2017 Sep 12. doi: 10.1519/JSC.0000000000002216. [Epub ahead of print]

PMID:
28922213
8.

A model to increase rehabilitation adherence to home exercise programmes in patients with varying levels of self-efficacy.

Picha KJ, Howell DM.

Musculoskeletal Care. 2018 Mar;16(1):233-237. doi: 10.1002/msc.1194. Epub 2017 Apr 12.

PMID:
28401666
9.

Glenohumeral and Hip Range-of-Motion and Strength Measures in Youth Baseball Athletes.

Picha KJ, Harding JL, Bliven KC.

J Athl Train. 2016 Jun 2;51(6):466-73. doi: 10.4085/1062-6050-51.7.09. Epub 2016 Jul 21.

10.

Engineering peptide therapeutics using MIMETIBODY™ technology.

Picha K, Huang C, Bugelski P, O'Neil K.

Methods Mol Biol. 2014;1088:125-45. doi: 10.1007/978-1-62703-673-3_9.

PMID:
24146401
11.

Inhalation delivery of protein therapeutics.

Kane C, O'Neil K, Conk M, Picha K.

Inflamm Allergy Drug Targets. 2013 Apr;12(2):81-7. Review.

PMID:
23517644
12.

GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice.

Parlevliet ET, Wang Y, Geerling JJ, Schröder-Van der Elst JP, Picha K, O'Neil K, Stojanovic-Susulic V, Ort T, Havekes LM, Romijn JA, Pijl H, Rensen PC.

PLoS One. 2012;7(11):e49152. doi: 10.1371/journal.pone.0049152. Epub 2012 Nov 2.

13.

Loss of toll-like receptor 3 function improves glucose tolerance and reduces liver steatosis in obese mice.

Wu LH, Huang CC, Adhikarakunnathu S, San Mateo LR, Duffy KE, Rafferty P, Bugelski P, Raymond H, Deutsch H, Picha K, Ward CK, Alexoupolou L, Flavell RA, Mbow ML, Susulic VS.

Metabolism. 2012 Nov;61(11):1633-45. doi: 10.1016/j.metabol.2012.04.015. Epub 2012 May 17.

PMID:
22607770
14.

A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes.

Scully MS, Ort TA, James IE, Bugelski PJ, Makropoulos DA, Deutsch HA, Pieterman EJ, van den Hoek AM, Havekes LM, Dubell WH, Wertheimer JD, Picha KM.

Exp Diabetes Res. 2011;2011:910159. doi: 10.1155/2011/910159. Epub 2011 Jun 30.

15.

MRI-based extended ordered values more efficiently differentiate cartilage loss in knees with and without joint space narrowing than region-specific approaches using MRI or radiography--data from the OA initiative.

Wirth W, Buck R, Nevitt M, Le Graverand MP, Benichou O, Dreher D, Davies RY, Lee JH, Picha K, Gimona A, Maschek S, Hudelmaier M, Eckstein F; OAI Investigators.

Osteoarthritis Cartilage. 2011 Jun;19(6):689-99. doi: 10.1016/j.joca.2011.02.011. Epub 2011 Feb 19.

16.

Rates of change and sensitivity to change in cartilage morphology in healthy knees and in knees with mild, moderate, and end-stage radiographic osteoarthritis: results from 831 participants from the Osteoarthritis Initiative.

Eckstein F, Nevitt M, Gimona A, Picha K, Lee JH, Davies RY, Dreher D, Benichou O, Le Graverand MP, Hudelmaier M, Maschek S, Wirth W; Osteoarthritis Initiative Investigators Group.

Arthritis Care Res (Hoboken). 2011 Mar;63(3):311-9. doi: 10.1002/acr.20370.

17.

Reference values and Z-scores for subregional femorotibial cartilage thickness--results from a large population-based sample (Framingham) and comparison with the non-exposed Osteoarthritis Initiative reference cohort.

Eckstein F, Yang M, Guermazi A, Roemer FW, Hudelmaier M, Picha K, Baribaud F, Wirth W, Felson DT.

Osteoarthritis Cartilage. 2010 Oct;18(10):1275-83. doi: 10.1016/j.joca.2010.07.010. Epub 2010 Aug 5.

18.

Sensitivity to change of cartilage morphometry using coronal FLASH, sagittal DESS, and coronal MPR DESS protocols--comparative data from the Osteoarthritis Initiative (OAI).

Wirth W, Nevitt M, Hellio Le Graverand MP, Benichou O, Dreher D, Davies RY, Lee J, Picha K, Gimona A, Maschek S, Hudelmaier M, Eckstein F; OAI investigators.

Osteoarthritis Cartilage. 2010 Apr;18(4):547-54. doi: 10.1016/j.joca.2009.12.003. Epub 2009 Dec 21.

19.

Development of mammalian production cell lines expressing CNTO736, a glucagon like peptide-1-MIMETIBODY: factors that influence productivity and product quality.

Dorai H, Nemeth JF, Cammaart E, Wang Y, Tang QM, Magill A, Lewis MJ, Raju TS, Picha K, O'Neil K, Ganguly S, Moore G.

Biotechnol Bioeng. 2009 May 1;103(1):162-76. doi: 10.1002/bit.22217.

PMID:
19137588
20.

Resistin is elevated following traumatic joint injury and causes matrix degradation and release of inflammatory cytokines from articular cartilage in vitro.

Lee JH, Ort T, Ma K, Picha K, Carton J, Marsters PA, Lohmander LS, Baribaud F, Song XY, Blake S.

Osteoarthritis Cartilage. 2009 May;17(5):613-20. doi: 10.1016/j.joca.2008.08.007. Epub 2008 Nov 1.

21.

CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice.

Parlevliet ET, Schröder-van der Elst JP, Corssmit EP, Picha K, O'Neil K, Stojanovic-Susulic V, Ort T, Havekes LM, Romijn JA, Pijl H.

J Pharmacol Exp Ther. 2009 Jan;328(1):240-8. doi: 10.1124/jpet.108.144154. Epub 2008 Oct 10.

22.

Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis.

Picha KM, Cunningham MR, Drucker DJ, Mathur A, Ort T, Scully M, Soderman A, Spinka-Doms T, Stojanovic-Susulic V, Thomas BA, O'Neil KT.

Diabetes. 2008 Jul;57(7):1926-34. doi: 10.2337/db07-1775. Epub 2008 Apr 21.

23.

Anti-human tissue factor antibody ameliorated intestinal ischemia reperfusion-induced acute lung injury in human tissue factor knock-in mice.

He X, Han B, Mura M, Li L, Cypel M, Soderman A, Picha K, Yang J, Liu M.

PLoS One. 2008 Jan 30;3(1):e1527. doi: 10.1371/journal.pone.0001527.

24.

Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model.

Berman DM, Cabrera O, Kenyon NM, Miller J, Tam SH, Khandekar VS, Picha KM, Soderman AR, Jordan RE, Bugelski PJ, Horninger D, Lark M, Davis JE, Alejandro R, Berggren PO, Zimmerman M, O'Neil JJ, Ricordi C, Kenyon NS.

Transplantation. 2007 Aug 15;84(3):308-15.

PMID:
17700154
25.

CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models.

Ngo CV, Picha K, McCabe F, Millar H, Tawadros R, Tam SH, Nakada MT, Anderson GM.

Int J Cancer. 2007 Mar 15;120(6):1261-7.

26.

The role of the C-terminal domain of protein tyrosine phosphatase-1B in phosphatase activity and substrate binding.

Picha KM, Patel SS, Mandiyan S, Koehn J, Wennogle LP.

J Biol Chem. 2007 Feb 2;282(5):2911-7. Epub 2006 Nov 29.

27.

The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth.

Nozawa F, Itami A, Saruc M, Kim M, Standop J, Picha KS, Cowan KH, Pour PM.

Pancreas. 2004 Jul;29(1):45-52.

PMID:
15211111
28.

Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.

Matsuzaki H, Schmied BM, Ulrich A, Standop J, Schneider MB, Batra SK, Picha KS, Pour PM.

Clin Cancer Res. 2001 Feb;7(2):407-14.

29.

Structure and function of hexameric helicases.

Patel SS, Picha KM.

Annu Rev Biochem. 2000;69:651-97. Review.

PMID:
10966472
30.
31.
32.

LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.

Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, Ovendale PJ, Picha KS, Morrissey PJ, Grabstein KH, Campos-Neto A, Reed SG.

J Immunol. 1998 Dec 1;161(11):6171-9.

34.

CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages.

Kennedy MK, Picha KS, Fanslow WC, Grabstein KH, Alderson MR, Clifford KN, Chin WA, Mohler KM.

Eur J Immunol. 1996 Feb;26(2):370-8.

PMID:
8617306
35.

Regulation of murine B cell growth and differentiation by CD30 ligand.

Shanebeck KD, Maliszewski CR, Kennedy MK, Picha KS, Smith CA, Goodwin RG, Grabstein KH.

Eur J Immunol. 1995 Aug;25(8):2147-53.

PMID:
7664777
36.

Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones.

Kennedy MK, Picha KS, Shanebeck KD, Anderson DM, Grabstein KH.

Eur J Immunol. 1994 Oct;24(10):2271-8.

PMID:
7925555
37.

Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death.

Ramsdell F, Seaman MS, Miller RE, Picha KS, Kennedy MK, Lynch DH.

Int Immunol. 1994 Oct;6(10):1545-53.

PMID:
7530039
38.

TNF abrogates the response of the CT.4S cell line to IL-4.

Ramsdell F, Picha KS, Seaman MS, Kennedy MK.

J Immunol Methods. 1994 Jan 3;167(1-2):299-301. No abstract available.

PMID:
8308285
39.

Induction of B cell costimulatory function by recombinant murine CD40 ligand.

Kennedy MK, Mohler KM, Shanebeck KD, Baum PR, Picha KS, Otten-Evans CA, Janeway CA Jr, Grabstein KH.

Eur J Immunol. 1994 Jan;24(1):116-23.

PMID:
7517359
40.

Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells.

Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, et al.

Cell. 1993 Dec 17;75(6):1157-67.

PMID:
7505204
42.

Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein.

McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD.

J Neuroimmunol. 1992 Jun;38(3):229-40.

PMID:
1376328
43.

In vivo effects of interleukin-1 beta on blood leukocytes in BB rats prone or resistant to diabetes.

Jobe LW, Vertrees S, Wilson CA, Jacobs C, Wilson DL, Picha KS, Baker P, Lernmark A.

Autoimmunity. 1992;11(4):233-7.

PMID:
1581467
44.

Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor.

Jacobs CA, Baker PE, Roux ER, Picha KS, Toivola B, Waugh S, Kennedy MK.

J Immunol. 1991 May 1;146(9):2983-9.

PMID:
1826702
45.

Bovine GM-CSF: molecular cloning and biological activity of the recombinant protein.

Maliszewski CR, Schoenborn MA, Cerretti DP, Wignall JM, Picha KS, Cosman D, Tushinski RJ, Gillis S, Baker PE.

Mol Immunol. 1988 Sep;25(9):843-50.

PMID:
3062386

Supplemental Content

Support Center